Wockhardt to launch Cefprozil, in the US

Wockhardt Ltd has announced that the Company got USFDA approval for antibiotic Cefprozil tablets (250 mg and 500 mg) and is all set to launch the product in the US market. Cefprozil, a Cephalosporin class of antibiotics, is used in the treatment of Respiratory Tract and Skin infections. The Company will launch Cefprozil, the generic version of brand Cefzil, sold by Bristol Myers Squibb.Several of our products have seen a dramatic increase in market share in the US, over the last six months. Cephalosporins have been an important product in our portfolio and Cefprozil will be a good addition to this range with a market potential of around $51 million, said the Companys Chairman Habil Khorakiwala. The eight FDA approval in just four months will significantly contribute to our growing visibility in USA, added Habil Khorakiwala.The Cefprozil tablets are manufactured at the Companys US FDA, certified formulation plant at Waluj, Maharashtra. The product was developed in-house.